A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.-MedSci.cn - 梅斯（MedSci）

A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.

Liu, H; Lei, W; Zhang, CT; Yang, CM; Wei, JY; Guo, QY; Guo, XJ; Chen, ZL; Lu, Y; Lu, ZM; Qian, WB

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务